Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLC092
MIFTS: 57

Glaucoma, Primary Open Angle

Categories: Genetic diseases, Eye diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Glaucoma, Primary Open Angle

About this section

MalaCards integrated aliases for Glaucoma, Primary Open Angle:

Name: Glaucoma, Primary Open Angle 57 75 38 73
Primary Open Angle Glaucoma 38 12 37 29 55 6 15
Glaucoma 1, Open Angle, E 57 75 29 13 6 73
Poag 57 75
Adult-Onset Primary Open Angle Glaucoma 75
Glaucoma, Open Angle, Primary ) 40
Primary Open Angle Glaucoma 1e 75
Chronic Simple Glaucoma 12
Glc1e 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
glaucoma, primary open angle:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 137760
Disease Ontology 12 DOID:1070
ICD10 33 H40.11 H40.1
ICD9CM 35 365.11
NCIt 50 C35394
SNOMED-CT 68 155122001 77075001
KEGG 37 H00612
SNOMED-CT via HPO 69 263681008 57190000
Sources

Summaries for Glaucoma, Primary Open Angle

About this section
UniProtKB/Swiss-Prot : 75 Glaucoma 1, open angle, E: A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. Glaucoma, primary open angle: A complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes.

MalaCards based summary : Glaucoma, Primary Open Angle, also known as primary open angle glaucoma, is related to glaucoma 3, primary congenital, a and glaucoma 1, open angle, a. An important gene associated with Glaucoma, Primary Open Angle is OPTN (Optineurin), and among its related pathways/superpathways are Ribosome biogenesis in eukaryotes and Elastic fibre formation. The drugs Travoprost and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include Eye, eye and testes, and related phenotypes are myopia and open angle glaucoma

OMIM : 57 Quigley (1993) reviewed adult-onset primary open angle glaucoma, which combines a particular abnormal appearance of the optic disc (optic nerve head) with a slowly progressive loss of visual sensitivity. Many patients with glaucoma have intraocular pressures above the normal range, although this cannot be considered part of the definition of the disease, since some patients have normal intraocular pressures. Changes in the optic disc, either inherited or acquired, contribute to the development of the disorder, which leads to visual loss from increasing nerve fiber layer atrophy. Quigley et al. (1994) stated that POAG should be reviewed as a multifactorial disorder. (137760)

Sources

Related Diseases for Glaucoma, Primary Open Angle

About this section

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1, Open Angle, a Glaucoma, Primary Open Angle
Glaucoma 1, Open Angle, P Glaucoma 1, Open Angle, I

Diseases related to Glaucoma, Primary Open Angle via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
# Related Disease Score Top Affiliating Genes
1 glaucoma 3, primary congenital, a 33.5 CYP1B1 MYOC OPTN
2 glaucoma 1, open angle, a 33.4 CYP1B1 MYOC OPTN
3 ocular hypertension 31.4 MYOC OPTN TMCO1
4 glaucoma, normal tension 31.0 LOXL1 OPTN
5 chronic closed-angle glaucoma 30.8 OPTN PHEX TGFB2
6 low tension glaucoma 30.3 CDKN2B-AS1 GAS7 MYOC OPTN WDR36
7 open-angle glaucoma 28.6 ASB10 CAV2 CDKN2B-AS1 CYP1B1 ELN GAS7
8 glaucoma 1, open angle, j 11.5
9 glaucoma 1, open angle, d 11.5
10 glaucoma 1, open angle, f 11.5
11 glaucoma 1, open angle, k 11.5
12 acrofrontofacionasal dysostosis 10.9 CYP1B1 OPTN
13 glaucoma-related pigment dispersion syndrome 10.9 CYP1B1 LOXL1
14 hydrophthalmos 10.8 CYP1B1 OPTN
15 excessive tearing 10.8 CYP1B1 MYOC OPTN
16 corneal edema 10.8 CYP1B1 MYOC OPTN
17 primary angle-closure glaucoma 10.8 CYP1B1 MYOC OPTN
18 axenfeld-rieger syndrome, type 2 10.8 ASB10 OPTN
19 traumatic glaucoma 10.8 OPTN PHEX
20 early-onset glaucoma 10.7 CYP1B1 MYOC
21 iris disease 10.7 LOXL1 OPTN PHEX
22 deafness, autosomal dominant 23 10.6 COCH SIX1
23 primary congenital glaucoma 10.6 CYP1B1 MYOC OPTN WDR36
24 neovascular glaucoma 10.6 OPTN TGFB2
25 aortic aneurysm 10.5 CDKN2B-AS1 ELN TGFB2
26 phacogenic glaucoma 10.5 ELN LOXL1 OPTN PHEX
27 optic nerve disease 10.5 ELN MYOC OPTN UBL4A
28 holoprosencephaly 2 10.4 SIX1 SIX6
29 lacrimal duct obstruction 10.3 OPTN SIX1
30 intraocular pressure quantitative trait locus 10.3 CDKN2B-AS1 CYP1B1 LOXL1 MYOC OPTN WDR36
31 optic disk drusen 10.0 ELN UBL4A
32 exfoliation syndrome 9.9
33 cataract 9.9
34 juvenile glaucoma 9.5 CYP1B1 ELN MYOC OPTN PHEX TGFB2

Comorbidity relations with Glaucoma, Primary Open Angle via Phenotypic Disease Network (PDN):


Chronic Closed-Angle Glaucoma Hypertension, Essential
Ocular Hypertension Ocular Hypotension
Open-Angle Glaucoma Residual Stage of Open Angle Glaucoma

Graphical network of the top 20 diseases related to Glaucoma, Primary Open Angle:



Diseases related to Glaucoma, Primary Open Angle
Sources

Symptoms & Phenotypes for Glaucoma, Primary Open Angle

About this section

Symptoms via clinical synopsis from OMIM:

57
Eyes:
open angle glaucoma
myopia

Misc:
more frequent among african americans


Clinical features from OMIM:

137760

Human phenotypes related to Glaucoma, Primary Open Angle:

32
# Description HPO Frequency HPO Source Accession
1 myopia 32 HP:0000545
2 open angle glaucoma 32 HP:0012108

GenomeRNAi Phenotypes related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.02 COCH MYOC OPTN SIX6 UBL4A
Sources

Drugs & Therapeutics for Glaucoma, Primary Open Angle

About this section

Drugs for Glaucoma, Primary Open Angle (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Travoprost Approved Phase 4,Phase 3,Phase 2,Not Applicable 157283-68-6 5282226
2
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 299-42-3 9294
3
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130209-82-4 5282380 5311221
4
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 90-82-4 7028
5
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 155206-00-1 5311027
6
Ketorolac Approved Phase 4,Not Applicable 74103-06-3, 66635-83-4 3826
7
Timolol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 26839-75-8 33624 5478
8
Brinzolamide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 138890-62-7 68844
9
Dorzolamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 120279-96-1 3154 5284549
10
Pilocarpine Approved, Investigational Phase 4,Not Applicable 54-71-7, 92-13-7 5910
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
12
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
13
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
14
Maleic acid Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 110-16-7 444266
15 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Nasal Decongestants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Vasoconstrictor Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
25 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Ketorolac Tromethamine Phase 4,Not Applicable
27 Adrenergic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Adrenergic Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
31 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Not Applicable
32 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Not Applicable
33 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Not Applicable
34 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Not Applicable 70359-46-5
35 Anesthetics Phase 4,Phase 1,Phase 2
36 Anti-Infective Agents Phase 4,Not Applicable
37 Anti-Infective Agents, Local Phase 4
38 Benzalkonium Compounds Phase 4
39 Anticoagulants Phase 4
40 Blood Substitutes Phase 4
41 Cloprostenol Phase 4,Phase 3
42 Contraceptive Agents Phase 4,Phase 3
43 Dextrans Phase 4
44 Lubricant Eye Drops Phase 4,Phase 3,Phase 2,Not Applicable
45 Luteolytic Agents Phase 4,Phase 3
46 Plasma Substitutes Phase 4
47 Mitomycins Phase 4,Phase 2,Phase 1,Not Applicable
48 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4,Phase 3,Not Applicable
49 Cholinergic Agents Phase 4,Not Applicable
50 Anti-Bacterial Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 328)
# Name Status NCT ID Phase Drugs
1 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
2 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
3 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
4 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
5 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
6 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
7 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
8 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
9 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
10 Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG) Completed NCT00913029 Phase 4 latanoprost/timolol
11 Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost Completed NCT03331770 Phase 4 Latanoprost Ophthalmic Product
12 Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00966940 Phase 4 Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution
13 Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
14 Efficacy And Safety of Pneumatic Trabeculoplasty Completed NCT01540331 Phase 4
15 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
16 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination Completed NCT00972257 Phase 4 treatment with dorzolamide/timolol;treatment with brimonidine/timolol
17 A Study of LUMIGAN® RC in the Clinical Setting Completed NCT01833741 Phase 4 Bimatoprost 0.01%
18 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
19 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
20 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
21 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
22 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
23 Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents Completed NCT01252888 Phase 4
24 Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents Completed NCT01252862 Phase 4
25 Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination Completed NCT00941096 Phase 4 Bimatoprost and Bimatoprost/Timolol fixed combination.
26 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
27 Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Completed NCT03104621 Phase 4 Benzalkonium chloride (BAK);0.0015% tafluprost
28 Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
29 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
30 A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness Completed NCT03204487 Phase 4 Tafluprost 15µg/ml
31 Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
32 24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost Completed NCT00444184 Phase 4 Travoprost/timolol fixed combination, travoprost
33 Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs Completed NCT00675207 Phase 4 Brimonidine purite 0.15%;Dorzolamide 2%;Brinzolamide 1%
34 Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
35 Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study Completed NCT00698438 Phase 4
36 Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy Completed NCT01263444 Phase 4 Brinzolamide 1% / timolol 0.5% Fixed Combination;Habitual prostaglandin monotherapy
37 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Completed NCT01443988 Phase 4 Travoprost
38 Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America Completed NCT01518244 Phase 4 Brinzolamide/timolol maleate fixed combination
39 Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma Completed NCT01471158 Phase 4 Brinzolamide/Timolol Maleate Fixed Combination (AZARGA);Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
40 Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol Completed NCT01336569 Phase 4 Travoprost 0.004%/timolol maleate 0.5% fixed combination
41 Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients. Completed NCT01155219 Phase 4 Geltim LP 1 mg/g;Xalatan
42 Dose, Effects and Characteristics of Pilocarpine Completed NCT00803803 Phase 4 Pilocarpine Concentration;Pilocarpine Frequency
43 Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Recruiting NCT01841450 Phase 4
44 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Recruiting NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
45 A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent Active, not recruiting NCT01252914 Phase 4
46 Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) Active, not recruiting NCT02863705 Phase 4 brimonidine tartrate/timolol malate Ophthalmic Solution;bimatoprost ophthalmic solution 0.01%
47 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study Active, not recruiting NCT03323164 Phase 4 Timolol Maleate;Brimonidine Tartrate
48 Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication Active, not recruiting NCT02868190 Phase 4
49 Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents Active, not recruiting NCT02873806 Phase 4 Topical travoprost;Tobramycin;Dexamethasone
50 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Active, not recruiting NCT01444040 Phase 4 Travoprost

Search NIH Clinical Center for Glaucoma, Primary Open Angle

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Glaucoma, Primary Open Angle cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Glaucoma, Primary Open Angle:
Renexus
Embryonic/Adult Cultured Cells Related to Glaucoma, Primary Open Angle:
Human retinal stem cells secreting CNTF PMIDs: 16805711 17508034 16505355 23049090 15684670 12581701 15223826 18830926
Sources

Genetic Tests for Glaucoma, Primary Open Angle

About this section

Genetic tests related to Glaucoma, Primary Open Angle:

# Genetic test Affiliating Genes
1 Primary Open Angle Glaucoma 29 OPTN
2 Primary Open Angle Glaucoma (adult Onset) 29
3 Glaucoma 1, Open Angle, E 29
Sources

Anatomical Context for Glaucoma, Primary Open Angle

About this section

MalaCards organs/tissues related to Glaucoma, Primary Open Angle:

41
Eye, Testes, Brain, Endothelial, Cortex, Retina, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Glaucoma, Primary Open Angle:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Ganglion Cell Layer Mature Ganglion Cells Affected by disease
Sources

Publications for Glaucoma, Primary Open Angle

About this section

Articles related to Glaucoma, Primary Open Angle:

(show top 50) (show all 1065)
# Title Authors Year
1
Association of catalase polymorphisms with primary open-angle glaucoma in a Chinese population. ( 28829657 )
2018
2
Systemic Medication Associations with Presumed Advanced or Uncontrolled Primary Open-Angle Glaucoma. ( 29433851 )
2018
3
Are we ready for genetic testing for primary open-angle glaucoma? ( 29379103 )
2018
4
The Efficacy of Transcorneal Electrical Stimulation for the Treatment of Primary Open-angle Glaucoma: A Pilot Study. ( 29415904 )
2018
5
Proteomic Analysis of Aqueous Humor from Primary Open Angle Glaucoma Patients on Drug Treatment Revealed Altered Complement Activation Cascade. ( 29901396 )
2018
6
Alzheimer's disease and primary open-angle glaucoma associated with vascular health in patients of African descent. ( 29855159 )
2018
7
Carbohydrate ingestion induces differential autonomic dysregulation in normal-tension glaucoma and primary open angle glaucoma. ( 29879162 )
2018
8
A new diagnostic model of primary open angle glaucoma based on FD-OCT parameters. ( 29977806 )
2018
9
Discontinuation of the herbal preparation <i>Hypericum perforatum</i>, also known as St John's wort, associated with improved intraocular pressure control in a patient on topical beta-blockers for primary open-angle glaucoma. ( 29930462 )
2018
10
Correction to: The Effect of Posture on Intraocular Pressure and Systemic Hemodynamic Parameters in Treated and Untreated Patients with Primary Open-Angle Glaucoma, by Katsanos, A., Dastiridou, A.I., Quaranta, L., Rulli, E., Riva, I., Dimasi, V., Tsironi, E.E., and Weinreb, R.N. J Ocul Pharmacol Ther 2017;33(8):598-603. DOI: 10.1089/jop.2017.0030. ( 29393727 )
2018
11
A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. ( 29945799 )
2018
12
Progression of Primary Open Angle Glaucoma in Diabetic and Non-diabetic Patients. ( 29447914 )
2018
13
The effect of trabeculectomy on serum brain-derived neurotrophic factor levels in primary open-angle glaucoma. ( 29417213 )
2018
14
Reduced Cerebral Blood Flow in the Visual Cortex and Its Correlation with Glaucomatous Structural Damage to the Retina in Patients with Mild to Moderate Primary Open Angle Glaucoma. ( 29952821 )
2018
15
Comparison of total/active ghrelin levels in primary open angle glaucoma, pseudoexfoliation glaucoma and pseudoexfoliation syndrome. ( 29862183 )
2018
16
Selective laser trabeculoplasty for primary open-angle glaucoma patients younger than 40 years. ( 29426447 )
2018
17
The relationship between HDAC6, CXCR3, and SIRT1 genes expression levels with progression of primary open-angle glaucoma. ( 29384425 )
2018
18
Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension. ( 29873009 )
2018
19
Simplifying &amp;quot;target&amp;quot; intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. ( 29582808 )
2018
20
Identification and genotype phenotype correlation of novel mutations in SIX6 gene in primary open angle glaucoma. ( 29405792 )
2018
21
Reduction of Intraocular Pressure by Additional Trabeculotomy Ab Externo in Eyes with Primary Open-angle Glaucoma. ( 29916998 )
2018
22
Genome-wide association study identifies seven novel susceptibility loci for primary open-angle glaucoma. ( 29452408 )
2018
23
Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis. ( 29169899 )
2018
24
Differentially expressed microRNAs in the aqueous humor of patients with exfoliation glaucoma or primary open-angle glaucoma. ( 29401312 )
2018
25
Noninvasive Detection of Mitochondrial Dysfunction in Ocular Hypertension and Primary Open-angle Glaucoma. ( 29750714 )
2018
26
Differentiating Occult Branch Retinal Artery Occlusion from Primary Open-angle Glaucoma. ( 29370018 )
2018
27
The risk of primary open angle glaucoma following vitreoretinal surgery- a population-based study. ( 29940165 )
2018
28
Pattern of peripapillary capillary density loss in ischemic optic neuropathy compared to that in primary open-angle glaucoma. ( 29320503 )
2018
29
Factors associated with developing a fear of falling in subjects with primary open-angle glaucoma. ( 29433472 )
2018
30
Screening for Primary Open-angle Glaucoma (POAG). ( 29870406 )
2018
31
Baseline Lamina Cribrosa Curvature and Subsequent Visual Field Progression Rate in Primary Open-Angle Glaucoma. ( 29945800 )
2018
32
A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. ( 29891935 )
2018
33
Testosterone Pathway Genetic Polymorphisms in Relation to Primary Open-Angle Glaucoma: An Analysis in Two Large Datasets. ( 29392307 )
2018
34
Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial. ( 29930448 )
2018
35
Two-year outcomes of ab interno trabeculectomy with the Trabectome for Chinese primary open angle glaucoma: a retrospective multicenter study. ( 29977805 )
2018
36
Analysis of toll-like receptor rs4986790 polymorphism in Saudi patients with primary open angle glaucoma. ( 27064537 )
2017
37
Magnetic Resonance Imaging of Optic Nerve Traction During Adduction in Primary Open-Angle Glaucoma With Normal Intraocular Pressure. ( 28829843 )
2017
38
[Primary Open Angle Glaucoma]. ( 28931182 )
2017
39
Association of single-nucleotide polymorphisms in non-coding regions of the TLR4 gene with primary open angle glaucoma in a Mexican population. ( 27892755 )
2017
40
Diurnal macular choroidal area fluctuation in normal and primary open angle glaucoma groups. ( 28861348 )
2017
41
Association of intraocular pressure related factors and retinal vessel diameter with optic disc rim area in subjects with and without primary open angle glaucoma. ( 28858414 )
2017
42
Contribution of Mutations in Known Mendelian Glaucoma Genes to Advanced Early-Onset Primary Open-Angle Glaucoma. ( 28282485 )
2017
43
[Studying the association between genetic polymorphism of growth factors and the development of primary open-angle glaucoma]. ( 28745651 )
2017
44
Comparison of self-measured diurnal intraocular pressure profiles using rebound tonometry between primary angle closure glaucoma and primary open angle glaucoma patients. ( 28333942 )
2017
45
Erratum: Predictors of Intraocular Pressure After Phacoemulsification in Primary Open-Angle Glaucoma Eyes with Wide Versus Narrower Angles (An American Ophthalmological Society Thesis). ( 29412193 )
2017
46
Clinical study of water drinking test and 24-hour intraocular pressure monitoring in patients with primary open angle glaucoma. ( 29043998 )
2017
47
Progressive Macula Vessel Density Loss in Primary Open-Angle Glaucoma: A Longitudinal Study. ( 28734815 )
2017
48
Association of Interleukin-1 gene clusters polymorphisms with primary open-angle glaucoma: a meta-analysis. ( 29179746 )
2017
49
[Significance of anti-myelin basic protein antibodies for ocular hydrodynamic disturbances in primary open-angle glaucoma]. ( 28745655 )
2017
50
Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue. ( 28053501 )
2017
Sources

Variations for Glaucoma, Primary Open Angle

About this section

UniProtKB/Swiss-Prot genetic disease variations for Glaucoma, Primary Open Angle:

75
# Symbol AA change Variation ID SNP ID
1 OPTN p.His26Asp VAR_021537 rs200710076
2 OPTN p.Glu50Lys VAR_021538 rs28939688
3 OPTN p.Glu103Asp VAR_021540
4 OPTN p.His486Arg VAR_021546 rs373425395

ClinVar genetic disease variations for Glaucoma, Primary Open Angle:

6
(show top 50) (show all 407)
# Gene Variation Type Significance SNP ID Assembly Location
1 OPTN NM_001008211.1(OPTN): c.148G> A (p.Glu50Lys) single nucleotide variant Pathogenic rs28939688 GRCh37 Chromosome 10, 13151270: 13151270
2 OPTN NM_001008211.1(OPTN): c.148G> A (p.Glu50Lys) single nucleotide variant Pathogenic rs28939688 GRCh38 Chromosome 10, 13109270: 13109270
3 OPTN OPTN, 2-BP INS, 691AG insertion Pathogenic
4 MYOC NM_000261.1(MYOC): c.1102C> T (p.Gln368Ter) single nucleotide variant Likely pathogenic rs74315329 GRCh37 Chromosome 1, 171605478: 171605478
5 MYOC NM_000261.1(MYOC): c.1102C> T (p.Gln368Ter) single nucleotide variant Likely pathogenic rs74315329 GRCh38 Chromosome 1, 171636338: 171636338
6 LTBP2 NM_000428.2(LTBP2): c.1484G> A (p.Arg495Gln) single nucleotide variant Likely pathogenic rs137854858 GRCh37 Chromosome 14, 75017969: 75017969
7 LTBP2 NM_000428.2(LTBP2): c.1484G> A (p.Arg495Gln) single nucleotide variant Likely pathogenic rs137854858 GRCh38 Chromosome 14, 74551266: 74551266
8 LTBP2 NM_000428.2(LTBP2): c.4250A> G (p.Gln1417Arg) single nucleotide variant Likely pathogenic rs137854863 GRCh37 Chromosome 14, 74971805: 74971805
9 LTBP2 NM_000428.2(LTBP2): c.4250A> G (p.Gln1417Arg) single nucleotide variant Likely pathogenic rs137854863 GRCh38 Chromosome 14, 74505102: 74505102
10 LTBP2 NM_000428.2(LTBP2): c.4912G> A (p.Val1638Met) single nucleotide variant Likely pathogenic rs137854860 GRCh37 Chromosome 14, 74969614: 74969614
11 LTBP2 NM_000428.2(LTBP2): c.4912G> A (p.Val1638Met) single nucleotide variant Likely pathogenic rs137854860 GRCh38 Chromosome 14, 74502911: 74502911
12 MYOC NM_000261.1(MYOC): c.227G> A (p.Arg76Lys) single nucleotide variant Benign/Likely benign rs2234926 GRCh37 Chromosome 1, 171621525: 171621525
13 MYOC NM_000261.1(MYOC): c.227G> A (p.Arg76Lys) single nucleotide variant Benign/Likely benign rs2234926 GRCh38 Chromosome 1, 171652385: 171652385
14 MYOC NM_000261.1(MYOC): c.855G> T (p.Thr285=) single nucleotide variant Benign/Likely benign rs146606638 GRCh37 Chromosome 1, 171605725: 171605725
15 MYOC NM_000261.1(MYOC): c.855G> T (p.Thr285=) single nucleotide variant Benign/Likely benign rs146606638 GRCh38 Chromosome 1, 171636585: 171636585
16 OPTN NM_001008211.1(OPTN): c.553-5C> T single nucleotide variant Benign rs2244380 GRCh37 Chromosome 10, 13158262: 13158262
17 OPTN NM_001008211.1(OPTN): c.553-5C> T single nucleotide variant Benign rs2244380 GRCh38 Chromosome 10, 13116262: 13116262
18 CARD10 NM_014550.3(CARD10): c.2485C> T (p.Arg829Trp) single nucleotide variant risk factor rs201794655 GRCh37 Chromosome 22, 37888801: 37888801
19 CARD10 NM_014550.3(CARD10): c.2485C> T (p.Arg829Trp) single nucleotide variant risk factor rs201794655 GRCh38 Chromosome 22, 37492794: 37492794
20 CARD10 NM_014550.3(CARD10): c.1210C> T (p.Arg404Trp) single nucleotide variant risk factor rs750643216 GRCh37 Chromosome 22, 37902372: 37902372
21 CARD10 NM_014550.3(CARD10): c.1210C> T (p.Arg404Trp) single nucleotide variant risk factor rs750643216 GRCh38 Chromosome 22, 37506365: 37506365
22 CARD10 NM_014550.3(CARD10): c.1024G> A (p.Val342Met) single nucleotide variant risk factor rs200148764 GRCh37 Chromosome 22, 37904575: 37904575
23 CARD10 NM_014550.3(CARD10): c.1024G> A (p.Val342Met) single nucleotide variant risk factor rs200148764 GRCh38 Chromosome 22, 37508568: 37508568
24 CARD10 NM_014550.3(CARD10): c.983C> T (p.Ala328Val) single nucleotide variant risk factor rs139006752 GRCh37 Chromosome 22, 37904616: 37904616
25 CARD10 NM_014550.3(CARD10): c.983C> T (p.Ala328Val) single nucleotide variant risk factor rs139006752 GRCh38 Chromosome 22, 37508609: 37508609
26 CARD10 NM_014550.3(CARD10): c.635G> A (p.Arg212His) single nucleotide variant risk factor rs1057519378 GRCh38 Chromosome 22, 37516037: 37516037
27 CARD10 NM_014550.3(CARD10): c.635G> A (p.Arg212His) single nucleotide variant risk factor rs1057519378 GRCh37 Chromosome 22, 37912044: 37912044
28 MYOC NM_000261.1(MYOC): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs878854408 GRCh37 Chromosome 1, 171605469: 171605469
29 MYOC NM_000261.1(MYOC): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs878854408 GRCh38 Chromosome 1, 171636329: 171636329
30 WDR36 NM_139281.2(WDR36): c.99C> G (p.Asp33Glu) single nucleotide variant Likely benign rs35629723 GRCh38 Chromosome 5, 111092387: 111092387
31 WDR36 NM_139281.2(WDR36): c.99C> G (p.Asp33Glu) single nucleotide variant Likely benign rs35629723 GRCh37 Chromosome 5, 110428085: 110428085
32 WDR36 NM_139281.2(WDR36): c.790A> G (p.Ile264Val) single nucleotide variant Benign rs11241095 GRCh38 Chromosome 5, 111103810: 111103810
33 WDR36 NM_139281.2(WDR36): c.790A> G (p.Ile264Val) single nucleotide variant Benign rs11241095 GRCh37 Chromosome 5, 110439509: 110439509
34 WDR36 NM_139281.2(WDR36): c.2181A> T (p.Val727=) single nucleotide variant Benign rs13186912 GRCh38 Chromosome 5, 111121006: 111121006
35 WDR36 NM_139281.2(WDR36): c.2181A> T (p.Val727=) single nucleotide variant Benign rs13186912 GRCh37 Chromosome 5, 110456704: 110456704
36 OPTN NM_001008211.1(OPTN): c.489A> G (p.Glu163=) single nucleotide variant Likely benign rs113811959 GRCh37 Chromosome 10, 13154572: 13154572
37 OPTN NM_001008211.1(OPTN): c.489A> G (p.Glu163=) single nucleotide variant Likely benign rs113811959 GRCh38 Chromosome 10, 13112572: 13112572
38 OPTN NM_001008211.1(OPTN): c.553-10G> A single nucleotide variant Benign rs11258210 GRCh38 Chromosome 10, 13116257: 13116257
39 OPTN NM_001008211.1(OPTN): c.553-10G> A single nucleotide variant Benign rs11258210 GRCh37 Chromosome 10, 13158257: 13158257
40 OPTN NM_001008211.1(OPTN): c.626+24G> A single nucleotide variant Benign rs11258211 GRCh38 Chromosome 10, 13116364: 13116364
41 OPTN NM_001008211.1(OPTN): c.626+24G> A single nucleotide variant Benign rs11258211 GRCh37 Chromosome 10, 13158364: 13158364
42 OPTN NM_001008212.1(OPTN): c.941A> T (p.Gln314Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs142812715 GRCh38 Chromosome 10, 13124053: 13124053
43 OPTN NM_001008212.1(OPTN): c.941A> T (p.Gln314Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs142812715 GRCh37 Chromosome 10, 13166053: 13166053
44 MYOC NM_000261.1(MYOC): c.*241A> G single nucleotide variant Uncertain significance rs186880389 GRCh37 Chromosome 1, 171604824: 171604824
45 MYOC NM_000261.1(MYOC): c.*241A> G single nucleotide variant Uncertain significance rs186880389 GRCh38 Chromosome 1, 171635684: 171635684
46 MYOC NM_000261.1(MYOC): c.*71G> A single nucleotide variant Uncertain significance rs886045564 GRCh37 Chromosome 1, 171604994: 171604994
47 MYOC NM_000261.1(MYOC): c.*71G> A single nucleotide variant Uncertain significance rs886045564 GRCh38 Chromosome 1, 171635854: 171635854
48 MYOC NM_000261.1(MYOC): c.1188G> A (p.Glu396=) single nucleotide variant Likely benign rs61730975 GRCh37 Chromosome 1, 171605392: 171605392
49 MYOC NM_000261.1(MYOC): c.1188G> A (p.Glu396=) single nucleotide variant Likely benign rs61730975 GRCh38 Chromosome 1, 171636252: 171636252
50 MYOC NM_000261.1(MYOC): c.865G> A (p.Asp289Asn) single nucleotide variant Uncertain significance rs767627671 GRCh37 Chromosome 1, 171605715: 171605715
Sources

Expression for Glaucoma, Primary Open Angle

About this section
Search GEO for disease gene expression data for Glaucoma, Primary Open Angle.
Sources

Pathways for Glaucoma, Primary Open Angle

About this section

Pathways related to Glaucoma, Primary Open Angle according to KEGG:

37
# Name Kegg Source Accession
1 Ribosome biogenesis in eukaryotes hsa03008

Pathways related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Elastic fibre formation 66
Show member pathways
 10.66 ELN LOXL1 TGFB2
Sources

GO Terms for Glaucoma, Primary Open Angle

About this section

Cellular components related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.02 COCH ELN LOXL1 MYOC TGFB2

Biological processes related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.26 ABCA4 CYP1B1 SIX6 WDR36
2 generation of neurons GO:0048699 9.16 SIX1 TGFB2
3 collagen fibril organization GO:0030199 8.8 CYP1B1 LOXL1 TGFB2
Sources

Sources for Glaucoma, Primary Open Angle

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....